Atrial fibrillation laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 28: | Line 28: | ||
*[[Coagulation]] studies ([[International normalized ratio|INR]]/[[aPTT]]) are usually performed, as [[anticoagulant]] [[medication]] may be commenced. | *[[Coagulation]] studies ([[International normalized ratio|INR]]/[[aPTT]]) are usually performed, as [[anticoagulant]] [[medication]] may be commenced. | ||
*High [[Sensitivity (tests)|sensitivity]] [[C-reactive protein]] ([[C-reactive protein|hs-CRP]]) could act as a predictive marker for [[cardiology|cardiac related]] complications and death.<ref name="pmid21962993">{{cite journal| author=Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A| title=Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study). | journal=Am J Cardiol | year= 2012 | volume= 109 | issue= 1 | pages= 95-9 | pmid=21962993 | doi=10.1016/j.amjcard.2011.08.010 | pmc=4062871 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21962993 }} </ref><ref name="pmid11282915">{{cite journal| author=Ridker PM| title=High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. | journal=Circulation | year= 2001 | volume= 103 | issue= 13 | pages= 1813-8 | pmid=11282915 | doi=10.1161/01.cir.103.13.1813 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11282915 }} </ref> | *High [[Sensitivity (tests)|sensitivity]] [[C-reactive protein]] ([[C-reactive protein|hs-CRP]]) could act as a predictive marker for [[cardiology|cardiac related]] complications and death.<ref name="pmid21962993">{{cite journal| author=Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A| title=Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study). | journal=Am J Cardiol | year= 2012 | volume= 109 | issue= 1 | pages= 95-9 | pmid=21962993 | doi=10.1016/j.amjcard.2011.08.010 | pmc=4062871 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21962993 }} </ref><ref name="pmid11282915">{{cite journal| author=Ridker PM| title=High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. | journal=Circulation | year= 2001 | volume= 103 | issue= 13 | pages= 1813-8 | pmid=11282915 | doi=10.1161/01.cir.103.13.1813 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11282915 }} </ref> | ||
*It is recommended to calculate [[time in therapeutic range]] ([[time in therapeutic range|TTR]]) for [[patients]] who are under [[treatment]] for [[atrial fibrillation]].<ref name="pmid34020968">{{cite journal| author=Perry M, Kemmis Betty S, Downes N, Andrews N, Mackenzie S, Guideline Committee| title=Atrial fibrillation: diagnosis and management-summary of NICE guidance. | journal=BMJ | year= 2021 | volume= 373 | issue= | pages= n1150 | pmid=34020968 | doi=10.1136/bmj.n1150 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34020968 }} </ref> | |||
**Based on NICE guideline usage of a sound method such as the Rosendaal method is recommended. | |||
**It is recommended to exclude measures of the first 6 weeks of [[treatment]]. | |||
**[[Time in therapeutic range]] ([[time in therapeutic range|TTR]]) is more trusted if it is calculated over at least 6 months of a period. | |||
==References== | ==References== | ||
Revision as of 19:35, 2 August 2021
 |
Resident Survival Guide |
| File:Critical Pathways.gif |
Sinus rhythm  |
Atrial fibrillation  |
|
Atrial Fibrillation Microchapters | |
|
Special Groups | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Cardioversion | |
|
Anticoagulation | |
|
Surgery | |
|
Case Studies | |
|
Atrial fibrillation laboratory findings On the Web | |
|
Directions to Hospitals Treating Atrial fibrillation laboratory findings | |
|
Risk calculators and risk factors for Atrial fibrillation laboratory findings | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]
Overview
Many cases of AF have no definite cause, it may be the result of various other problems (blood tests of thyroid function are required, especially for a first episode of AF, when the ventricular rate is difficult to control, or when AF recurs unexpectedly after cardioversion).
Laboratory Findings
- Renal function and electrolytes are routinely performed in patients suffering from atrial fibrillation.
- Thyroid function tests : Thyroid-stimulating hormone (TSH) is commonly suppressed in hyperthyroidism and of relevance if amiodarone is administered for treatment.
- Complete blood count
- Cardiac markers : In acute-onset AF associated with chest pain, cardiac troponins or other markers of damage to the heart muscle may be ordered.
- Coagulation studies (INR/aPTT) are usually performed, as anticoagulant medication may be commenced.
- High sensitivity C-reactive protein (hs-CRP) could act as a predictive marker for cardiac related complications and death.[1][2]
- It is recommended to calculate time in therapeutic range (TTR) for patients who are under treatment for atrial fibrillation.[3]
- Based on NICE guideline usage of a sound method such as the Rosendaal method is recommended.
- It is recommended to exclude measures of the first 6 weeks of treatment.
- Time in therapeutic range (TTR) is more trusted if it is calculated over at least 6 months of a period.
References
- ↑ Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A (2012). "Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study)". Am J Cardiol. 109 (1): 95–9. doi:10.1016/j.amjcard.2011.08.010. PMC 4062871. PMID 21962993.
- ↑ Ridker PM (2001). "High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease". Circulation. 103 (13): 1813–8. doi:10.1161/01.cir.103.13.1813. PMID 11282915.
- ↑ Perry M, Kemmis Betty S, Downes N, Andrews N, Mackenzie S, Guideline Committee (2021). "Atrial fibrillation: diagnosis and management-summary of NICE guidance". BMJ. 373: n1150. doi:10.1136/bmj.n1150. PMID 34020968 Check
|pmid=value (help).